RECRUITING

The Effects of Glucagon on Hepatic Metabolism in People With Type 2 Diabetes After Caloric Restriction

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Caloric restriction (and RYGB) improves insulin action and lowers fasting glucose, glucagon and EGP, without changes in postprandial EGP and glucagon concentrations. Caloric restriction also improves hepatic steatosis and lowers fasting AA. These changes may represent restoration of glucagon's hepatic actions. This experiment will determine whether caloric restriction improves glucagon's actions on hepatic amino acid, carbohydrate and lipid metabolism in T2DM in comparison to a baseline experiment performed separately in people with T2DM.

Official Title

The Effects of Glucagon on Hepatic Metabolism in People With Type 2 Diabetes After Caloric Restriction

Quick Facts

Study Start:2022-12-15
Study Completion:2026-12-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05499702

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:25 Years to 65 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * We will recruit up to 20 weight-stable, subjects with type 2 diabetes
  2. * BMI ≥ 28 Kg/M2
  3. * Diabetes is managed by diet alone or a combination of oral agents
  1. * History of prior upper abdominal surgery e.g. gastric banding, pyloroplasty, vagotomy.
  2. * Active systemic illness or malignancy.
  3. * Symptomatic macrovascular or microvascular disease.
  4. * Contraindications to MRI (e.g. metal implants, claustrophobia).
  5. * Hematocrit \< 35%
  6. * TSH \< 0.4 or \> 5.5.
  7. * Consumption of \> 2 alcohol drinks per day or \> 14 per week or a positive AUDIT questionnaire.

Contacts and Locations

Study Contact

Jeanette Laugen
CONTACT
5072558110
Laugen.Jeanette@mayo.edu

Principal Investigator

Adrian Vella
PRINCIPAL_INVESTIGATOR
Mayo Clinic

Study Locations (Sites)

Mayo Clinic in Rochester
Rochester, Minnesota, 55905
United States

Collaborators and Investigators

Sponsor: Adrian Vella

  • Adrian Vella, PRINCIPAL_INVESTIGATOR, Mayo Clinic

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-12-15
Study Completion Date2026-12-31

Study Record Updates

Study Start Date2022-12-15
Study Completion Date2026-12-31

Terms related to this study

Keywords Provided by Researchers

  • glucagon
  • insulin resistance
  • caloric restriction
  • hepatic steatosis
  • amino acid metabolism

Additional Relevant MeSH Terms

  • Type2diabetes